JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB108624

Anti-CYP3A5 抗体 [EPR4396]

Anti-CYP3A5 antibody [EPR4396]

Be the first to review this product! Submit a review

|

(8 Publications)

Rabbit Recombinant Monoclonal CYP3A5 antibody. Suitable for IP, WB, IHC-P and reacts with Human samples. Cited in 8 publications.

別名を表示する

Cytochrome P450 3A5, CYPIIIA5, Cytochrome P450-PCN3, CYP3A5

12 Images
Western blot - Anti-CYP3A5 antibody [EPR4396] (AB108624)
  • WB

Unknown

Western blot - Anti-CYP3A5 antibody [EPR4396] (AB108624)

All lanes:

Western blot - Anti-CYP3A5 antibody [EPR4396] (ab108624) at 1/1000 dilution

Lane 1:

Human fetal liver tissue lysate at 10 µg

Lane 2:

Human fetal colon tissue lysate at 10 µg

Predicted band size: 57 kDa

false

Western blot - Anti-CYP3A5 antibody [EPR4396] (AB108624)
  • WB

Lab

Western blot - Anti-CYP3A5 antibody [EPR4396] (AB108624)

Blocking buffer and concentration : 5% NFDM/TBST.

Diluting buffer and concentration : 5% NFDM /TBST.

All lanes:

Western blot - Anti-CYP3A5 antibody [EPR4396] (ab108624) at 1/400 dilution

All lanes:

Human fetal liver tissue lysate at 20 µg

Secondary

All lanes:

HRP-conjugated anti-rabbit IgG, specific to the non-reduced form of IgG at 1/1000 dilution

Predicted band size: 57 kDa

Observed band size: 52 kDa

false

Western blot - Anti-CYP3A5 antibody [EPR4396] (AB108624)
  • WB

Lab

Western blot - Anti-CYP3A5 antibody [EPR4396] (AB108624)

Blocking buffer and concentration : 5% NFDM/TBST.

Diluting buffer and concentration : 5% NFDM /TBST.

All lanes:

Western blot - Anti-CYP3A5 antibody [EPR4396] (ab108624) at 1/1000 dilution

All lanes:

Human fetal liver tissue lysate at 20 µg

Secondary

All lanes:

HRP-conjugated anti-rabbit IgG, specific to the non-reduced form of IgG at 1/1000 dilution

Predicted band size: 57 kDa

Observed band size: 52 kDa

false

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-CYP3A5 antibody [EPR4396] (AB108624)
  • IHC-P

Unknown

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-CYP3A5 antibody [EPR4396] (AB108624)

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) analysis of normal human kidney tissue labelling CYP3A5 with unpurified ab108624. Positive staining is shown.

Perform heat mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol.

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-CYP3A5 antibody [EPR4396] (AB108624)
  • IHC-P

Unknown

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-CYP3A5 antibody [EPR4396] (AB108624)

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) analysis of normal human tonsil tissue labelling CYP3A5 with unpurified ab108624. Negative staining is shown.

Perform heat mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol.

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-CYP3A5 antibody [EPR4396] (AB108624)
  • IHC-P

Unknown

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-CYP3A5 antibody [EPR4396] (AB108624)

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) analysis of normal human colon tissue labelling CYP3A5 with unpurified ab108624. Positive staining is shown.

Perform heat mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol.

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-CYP3A5 antibody [EPR4396] (AB108624)
  • IHC-P

Lab

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-CYP3A5 antibody [EPR4396] (AB108624)

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) analysis of human liver tissue labelling CYP3A5 with purified ab108624 at 1/250. Heat mediated antigen retrieval was performed using Tris/EDTA buffer pH 9. A prediluted HRP-polymer conjugated anti-rabbit IgG was used as the secondary antibody. Counterstained with Hematoxylin.

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-CYP3A5 antibody [EPR4396] (AB108624)
  • IHC-P

Lab

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-CYP3A5 antibody [EPR4396] (AB108624)

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) analysis of human liver tissue labelling CYP3A5 with unpurified ab108624 at 1/80. Heat mediated antigen retrieval was performed using Tris/EDTA buffer pH 9. A prediluted HRP-polymer conjugated anti-rabbit IgG was used as the secondary antibody. Counterstained with Hematoxylin.

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-CYP3A5 antibody [EPR4396] (AB108624)
  • IHC-P

Unknown

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-CYP3A5 antibody [EPR4396] (AB108624)

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) analysis of normal human breast tissue labelling CYP3A5 with unpurified ab108624. Negative staining is shown.

Perform heat mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol.

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-CYP3A5 antibody [EPR4396] (AB108624)
  • IHC-P

Unknown

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-CYP3A5 antibody [EPR4396] (AB108624)

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) analysis of human skeletal muscle tissue labelling CYP3A5 with unpurified ab108624. Negative staining is shown.

Perform heat mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol.

Immunoprecipitation - Anti-CYP3A5 antibody [EPR4396] (AB108624)
  • IP

Lab

Immunoprecipitation - Anti-CYP3A5 antibody [EPR4396] (AB108624)

ab108624 (unpurified) at 1/20 immunoprecipitating CYP3A5 in human fetal liver tissue lysate (Lane 1). Lane 2 - PBS. For western blotting, a HRP-conjugated anti-rabbit IgG, specific to the non-reduced form of IgG was used as the secondary antibody (1/1500).

Blocking buffer and concentration : 5% NFDM/TBST.

Diluting buffer and concentration : 5% NFDM /TBST.

All lanes:

Immunoprecipitation - Anti-CYP3A5 antibody [EPR4396] (ab108624)

Predicted band size: 57 kDa

Observed band size: 52 kDa

false

Immunoprecipitation - Anti-CYP3A5 antibody [EPR4396] (AB108624)
  • IP

Unknown

Immunoprecipitation - Anti-CYP3A5 antibody [EPR4396] (AB108624)

ab108624 (purified) at 1/50 immunoprecipitating CYP3A5 in human fetal liver tissue lysate (Lane 1). Lane 2 - PBS. For western blotting, a HRP-conjugated anti-rabbit IgG, specific to the non-reduced form of IgG was used as the secondary antibody (1/1500).

Blocking buffer and concentration : 5% NFDM/TBST.

Diluting buffer and concentration : 5% NFDM /TBST.

All lanes:

Immunoprecipitation - Anti-CYP3A5 antibody [EPR4396] (ab108624)

Predicted band size: 57 kDa

Observed band size: 52 kDa

false

関連する標識済み抗体及び組成の異なる製品 (1)

  • Carrier free

    Anti-CYP3A5 antibody [EPR4396] - BSA and Azide free

Key facts

宿主種

Rabbit

クローン性

Monoclonal

クローン番号

EPR4396

アイソタイプ

IgG

キャリアフリー

No

交差種

Human

アプリケーション

WB, IP, IHC-P

applications

免疫原

The exact immunogen used to generate this antibody is proprietary information.

style
left-column

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "IP" : {"fullname" : "Immunoprecipitation", "shortname":"IP"}, "WB" : {"fullname" : "Western blot", "shortname":"WB"}, "IHCP" : {"fullname" : "Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)", "shortname":"IHC-P"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "IP-species-checked": "testedAndGuaranteed", "IP-species-dilution-info": "1/50", "IP-species-notes": "<p><strong>For unpurified use at 1/20.</strong></p> Perform heat-mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol.", "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "1/1000", "WB-species-notes": "<p><strong>For unpurified use at 1/400.</strong></p>", "IHCP-species-checked": "testedAndGuaranteed", "IHCP-species-dilution-info": "1/250", "IHCP-species-notes": "<p><strong>For unpurified use at 1/80.</strong></p> Perform heat-mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol." } } }
style
left-column
style
left-column

製品の詳細

style
left-column

出荷温度及び保存条件

製品の状態
Liquid
精製方法
Affinity purification Protein A
バッファー組成
pH: 7.2 - 7.4 Preservative: 0.01% Sodium azide Constituents: 59% PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA
出荷温度
Blue Ice
短期保存期間
1-2 weeks
短期保存温度
+4°C
長期保存温度
-20°C
分注に関する情報
Upon delivery aliquot
保管に関する情報
Stable for 12 months at -20°C
style
left-column

補足情報

This supplementary information is collated from multiple sources and compiled automatically.

CYP3A5 also known as cytochrome P450 3A5 is an enzyme involved in drug metabolism. It is part of the cytochrome P450 superfamily. The enzyme has a molecular weight of approximately 57 kDa. Scientists have identified CYP3A5 as an important player in the oxidative metabolism of various xenobiotics and endogenous compounds. It is predominantly expressed in the liver but is also found in the kidney and intestines. Variability in CYP3A5 expression across individuals can significantly impact drug clearance rates and pharmacokinetics.
Biological function summary

CYP3A5 plays a significant role in the metabolism of many drugs and steroid hormones. This ability stems from its function as a monooxygenase in the metabolism of both exogenous and endogenous substrates. CYP3A5 is not necessarily part of a larger enzyme complex but it often acts in concert with other CYP3A enzymes within the liver. Variability in gene expression can result in different metabolizing capacities among individuals which scientists often relate to genetic polymorphisms that affect the CYP3A5*3 allele.

Pathways

CYP3A5 is integral to the steroid hormone biosynthesis and drug metabolism pathways. It interacts closely with CYP3A4 frequently working together to metabolize substrates such as cortisol and testosterone. The pathway involving drug metabolism highlights the importance of these enzymes in the detoxification and clearance of pharmaceuticals which may influence drug efficacy and safety in patients. Through its involvement in steroid hormone biosynthesis CYP3A5 coordinates with other enzymes to regulate the levels of active hormones contributing to hormonal balance.

Scientists have linked variations in CYP3A5 expression and activity to hypertension and cancer. The role of CYP3A5 in hypertension is of particular interest due to its involvement in the metabolism of cortisol a hormone influencing blood pressure. Additionally altered CYP3A5 activity can affect the activation and clearance of chemotherapeutic agents impacting treatment outcomes in cancer. Researchers have noted that CYP3A5 shares functional relationships with proteins such as P-glycoprotein which plays roles in drug transport and resistance further connecting it to treatment efficacy and safety in these diseases.
style
left-column
style
left-column

製品プロトコール

For this product, it's our understanding that no specific protocols are required. You can visit:
style
left-column

ターゲットの情報

A cytochrome P450 monooxygenase involved in the metabolism of steroid hormones and vitamins (PubMed : 10681376, PubMed : 11093772, PubMed : 12865317, PubMed : 2732228). Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase (NADPH--hemoprotein reductase). Catalyzes the hydroxylation of carbon-hydrogen bonds (PubMed : 10681376, PubMed : 11093772, PubMed : 12865317, PubMed : 2732228). Exhibits high catalytic activity for the formation of catechol estrogens from 17beta-estradiol (E2) and estrone (E1), namely 2-hydroxy E1 and E2 (PubMed : 12865317). Catalyzes 6beta-hydroxylation of the steroid hormones testosterone, progesterone, and androstenedione (PubMed : 2732228). Catalyzes the oxidative conversion of all-trans-retinol to all-trans-retinal, a rate-limiting step for the biosynthesis of all-trans-retinoic acid (atRA) (PubMed : 10681376). Further metabolizes all trans-retinoic acid (atRA) to 4-hydroxyretinoate and may play a role in hepatic atRA clearance (PubMed : 11093772). Also involved in the oxidative metabolism of xenobiotics, including calcium channel blocking drug nifedipine and immunosuppressive drug cyclosporine (PubMed : 2732228).
See full target information Cytochrome P450 3A5
style
left-column

文献 (8)

Recent publications for all applications. Explore the full list and refine your search

Nature cancer 4:1362-1381 PubMed37679568

2023

Persister cell phenotypes contribute to poor patient outcomes after neoadjuvant chemotherapy in PDAC.

Applications

Unspecified application

Species

Unspecified reactive species

Xu Zhou,Jingyu An,Roma Kurilov,Benedikt Brors,Kai Hu,Teresa Peccerella,Stephanie Roessler,Katrin Pfütze,Angela Schulz,Stephan Wolf,Nicolas Hohmann,Dirk Theile,Max Sauter,Jürgen Burhenne,Shigenori Ei,Ulrike Heger,Oliver Strobel,Simon T Barry,Christoph Springfeld,Christine Tjaden,Frank Bergmann,Markus Büchler,Thilo Hackert,Franco Fortunato,John P Neoptolemos,Peter Bailey

Journal of medicinal chemistry 63:1415-1433 PubMed31965799

2020

Clobetasol Propionate Is a Heme-Mediated Selective Inhibitor of Human Cytochrome P450 3A5.

Applications

Unspecified application

Species

Unspecified reactive species

William C Wright,Jude Chenge,Jingheng Wang,Hazel M Girvan,Lei Yang,Sergio C Chai,Andrew D Huber,Jing Wu,Peter O Oladimeji,Andrew W Munro,Taosheng Chen

Oncology reports 42:973-990 PubMed31322243

2019

miR‑543 acts as a novel oncogene in oral squamous cell carcinoma by targeting CYP3A5.

Applications

Unspecified application

Species

Unspecified reactive species

Liping Wang,Weihong Chen,Jun Zha,Yongyong Yan,Yongxiang Wei,Xili Chen,Xinxin Zhu,Linhu Ge

Pharmacotherapy 39:67-76 PubMed30537010

2019

TLR9 rs352139 Genetic Variant Promotes Tacrolimus Elimination in Chinese Liver Transplant Patients During the Early Posttransplantation Period.

Applications

Unspecified application

Species

Unspecified reactive species

Baochi Ou,Yuan Liu,Tao Zhang,Yahuang Sun,Jiayi Chen,Zhihai Peng

Biochemical pharmacology 160:92-109 PubMed30566892

2018

RNA interference screen identifies NAA10 as a regulator of PXR transcription.

Applications

Unspecified application

Species

Unspecified reactive species

Peter O Oladimeji,William C Wright,Jing Wu,Taosheng Chen

Liver international : official journal of the International Association for the Study of the Liver 38:724-732 PubMed28941036

2017

Association of donor small ubiquitin-like modifier 4 rs237025 genetic variant with tacrolimus elimination in the early period after liver transplantation.

Applications

Unspecified application

Species

Unspecified reactive species

Tao Zhang,Yuan Liu,Rong Zeng,Qi Ling,Peihao Wen,Junwei Fan,Zhihai Peng

International journal of molecular medicine 39:101-112 PubMed27959388

2016

A tryptophan derivative, ITE, enhances liver cell metabolic functions in vitro.

Applications

Unspecified application

Species

Unspecified reactive species

Xiaoqian Zhang,Juan Lu,Bin He,Lingling Tang,Xiaoli Liu,Danhua Zhu,Hongcui Cao,Yingjie Wang,Lanjuan Li

European journal of histochemistry : EJH 60:2614 PubMed27349315

2016

Immunohistochemical markers of CYP3A4 and CYP3A7: a new tool towards personalized pharmacotherapy of hepatocellular carcinoma.

Applications

Unspecified application

Species

Unspecified reactive species

D Fanni,M Manchia,F Lai,C Gerosa,R Ambu,G Faa
View all publications
style
left-column
style
left-column

Abcam product promise

当社は、高品質な試薬を通じてお客様の研究を力強くサポートすることをお約束いたします。ご使用いただく各段階で、常にお客様をサポートできる体制を整えております。万が一、製品が期待通りに機能しない場合は、「Abcam Product Promise」による当社保証制度に基づき、安心してご利用いただけます。
保証に関する詳細については利用規約をご確認ください。
style
left-column
style
right-column

関連製品

Select an associated product type
Alternative Product
Primary Antibodies

AB56076

Anti-CYP3A5 antibody [F18 P3 B6]

primary-antibodies

cyp3a5-antibody-f18-p3-b6-ab56076

0

(1 reviews)

style
bg-slate-100

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com